The emerging role of mitochondrial targeting in kidney disease

Research output: Chapter in Book/Report/Conference proceedingChapter

16 Citations (Scopus)

Abstract

Renal disease affects millions of people worldwide, imposing an enormous financial burden for health-care systems. Recent evidence suggests that mitochondria play an important role in the pathogenesis of different forms of renal disease, including genetic defects, acute kidney injury, chronic kidney disease, aging, renal tumors, and transplant nephropathy. Renal mitochondrial abnormalities and dysfunction affect several cellular pathways, leading to increased oxidative stress, apoptosis, microvascular loss, and fibrosis, all of which compromise renal function. Over recent years, compounds that specifically target mitochondria have emerged as promising therapeutic options for patients with renal disease. Although the most compelling evidence is based on preclinical studies, several compounds are currently being tested in clinical trials. This chapter provides an overview of the involvement of mitochondrial dysfunction in renal disease and summarizes the current knowledge on mitochondria-targeted strategies to attenuate renal disease.

Original languageEnglish (US)
Title of host publicationHandbook of Experimental Pharmacology
PublisherSpringer New York LLC
Pages229-250
Number of pages22
Volume240
DOIs
StatePublished - 2017

Publication series

NameHandbook of Experimental Pharmacology
Volume240
ISSN (Print)0171-2004
ISSN (Electronic)1865-0325

Fingerprint

Kidney Diseases
Kidney
Mitochondria
Transplants
Oxidative stress
Health care
Inborn Genetic Diseases
Tumors
Aging of materials
Chronic Renal Insufficiency
Acute Kidney Injury
Apoptosis
Defects
Oxidative Stress
Fibrosis
Clinical Trials
Delivery of Health Care

Keywords

  • ATP
  • Cardiolipin
  • Kidney
  • Mitochondria

ASJC Scopus subject areas

  • Biochemistry
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Eirin, A., Lerman, A., & Lerman, L. O. (2017). The emerging role of mitochondrial targeting in kidney disease. In Handbook of Experimental Pharmacology (Vol. 240, pp. 229-250). (Handbook of Experimental Pharmacology; Vol. 240). Springer New York LLC. https://doi.org/10.1007/164_2016_6

The emerging role of mitochondrial targeting in kidney disease. / Eirin, Alfonso; Lerman, Amir; Lerman, Lilach O.

Handbook of Experimental Pharmacology. Vol. 240 Springer New York LLC, 2017. p. 229-250 (Handbook of Experimental Pharmacology; Vol. 240).

Research output: Chapter in Book/Report/Conference proceedingChapter

Eirin, A, Lerman, A & Lerman, LO 2017, The emerging role of mitochondrial targeting in kidney disease. in Handbook of Experimental Pharmacology. vol. 240, Handbook of Experimental Pharmacology, vol. 240, Springer New York LLC, pp. 229-250. https://doi.org/10.1007/164_2016_6
Eirin A, Lerman A, Lerman LO. The emerging role of mitochondrial targeting in kidney disease. In Handbook of Experimental Pharmacology. Vol. 240. Springer New York LLC. 2017. p. 229-250. (Handbook of Experimental Pharmacology). https://doi.org/10.1007/164_2016_6
Eirin, Alfonso ; Lerman, Amir ; Lerman, Lilach O. / The emerging role of mitochondrial targeting in kidney disease. Handbook of Experimental Pharmacology. Vol. 240 Springer New York LLC, 2017. pp. 229-250 (Handbook of Experimental Pharmacology).
@inbook{2deb0ca0e72f41d3b6fdfce9859fbfb3,
title = "The emerging role of mitochondrial targeting in kidney disease",
abstract = "Renal disease affects millions of people worldwide, imposing an enormous financial burden for health-care systems. Recent evidence suggests that mitochondria play an important role in the pathogenesis of different forms of renal disease, including genetic defects, acute kidney injury, chronic kidney disease, aging, renal tumors, and transplant nephropathy. Renal mitochondrial abnormalities and dysfunction affect several cellular pathways, leading to increased oxidative stress, apoptosis, microvascular loss, and fibrosis, all of which compromise renal function. Over recent years, compounds that specifically target mitochondria have emerged as promising therapeutic options for patients with renal disease. Although the most compelling evidence is based on preclinical studies, several compounds are currently being tested in clinical trials. This chapter provides an overview of the involvement of mitochondrial dysfunction in renal disease and summarizes the current knowledge on mitochondria-targeted strategies to attenuate renal disease.",
keywords = "ATP, Cardiolipin, Kidney, Mitochondria",
author = "Alfonso Eirin and Amir Lerman and Lerman, {Lilach O}",
year = "2017",
doi = "10.1007/164_2016_6",
language = "English (US)",
volume = "240",
series = "Handbook of Experimental Pharmacology",
publisher = "Springer New York LLC",
pages = "229--250",
booktitle = "Handbook of Experimental Pharmacology",

}

TY - CHAP

T1 - The emerging role of mitochondrial targeting in kidney disease

AU - Eirin, Alfonso

AU - Lerman, Amir

AU - Lerman, Lilach O

PY - 2017

Y1 - 2017

N2 - Renal disease affects millions of people worldwide, imposing an enormous financial burden for health-care systems. Recent evidence suggests that mitochondria play an important role in the pathogenesis of different forms of renal disease, including genetic defects, acute kidney injury, chronic kidney disease, aging, renal tumors, and transplant nephropathy. Renal mitochondrial abnormalities and dysfunction affect several cellular pathways, leading to increased oxidative stress, apoptosis, microvascular loss, and fibrosis, all of which compromise renal function. Over recent years, compounds that specifically target mitochondria have emerged as promising therapeutic options for patients with renal disease. Although the most compelling evidence is based on preclinical studies, several compounds are currently being tested in clinical trials. This chapter provides an overview of the involvement of mitochondrial dysfunction in renal disease and summarizes the current knowledge on mitochondria-targeted strategies to attenuate renal disease.

AB - Renal disease affects millions of people worldwide, imposing an enormous financial burden for health-care systems. Recent evidence suggests that mitochondria play an important role in the pathogenesis of different forms of renal disease, including genetic defects, acute kidney injury, chronic kidney disease, aging, renal tumors, and transplant nephropathy. Renal mitochondrial abnormalities and dysfunction affect several cellular pathways, leading to increased oxidative stress, apoptosis, microvascular loss, and fibrosis, all of which compromise renal function. Over recent years, compounds that specifically target mitochondria have emerged as promising therapeutic options for patients with renal disease. Although the most compelling evidence is based on preclinical studies, several compounds are currently being tested in clinical trials. This chapter provides an overview of the involvement of mitochondrial dysfunction in renal disease and summarizes the current knowledge on mitochondria-targeted strategies to attenuate renal disease.

KW - ATP

KW - Cardiolipin

KW - Kidney

KW - Mitochondria

UR - http://www.scopus.com/inward/record.url?scp=85027396088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027396088&partnerID=8YFLogxK

U2 - 10.1007/164_2016_6

DO - 10.1007/164_2016_6

M3 - Chapter

C2 - 27316914

AN - SCOPUS:85027396088

VL - 240

T3 - Handbook of Experimental Pharmacology

SP - 229

EP - 250

BT - Handbook of Experimental Pharmacology

PB - Springer New York LLC

ER -